Answers are grounded in this paper and cite their sources.
Neuropsychiatric morbidity after decompressive craniectomy (DC) is increasingly recognised, but prevalence and trajectories remain unclear. We aimed to examine psychiatric and cognitive outcomes post-DC. The systematic review and meta-analysis (PROSPERO-CRD 420251106085) followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Medline, Embase, PsycINFO, PubMed, Scopus, and Web of Science databases were searched through October 2025. Eligible studies included validated psychometric and cognitive tools to assess psychiatric and cognitive outcomes post-DC. The Random-effects meta-analysis was used to estimate the pooled prevalence. Heterogeneity was assessed using I², and meta-regression explored sources of variability. Longitudinal outcomes after cranioplasty were analysed separately. Twenty-four studies were included in the qualitative analysis (N = 877), and 12 were included in the meta-analysis (N = 305). The pooled prevalence of depression was 47% (95% confidence interval [CI]: 40–54%, I²=20.2% [95% CI: 0–58.9%]), and anxiety, from four studies, was 46% (95% CI: 38–54%, I²=0% [95% CI: 0–84.7%]). Limited longitudinal data available from two studies showed a reduction in anxiety and depression after cranioplasty, with large effect sizes at 12 months (anxiety: p < 0.001, g = 5.36; depression: p < 0.001, g = 5.04). However, the effect sizes may have been inflated due to small cohorts included in these studies. Among the six studies reporting severity, the rates of moderate depression ranged from 8.3% to 45.5%, and severe depression from 9.1% to 36.4% across assessment tools. Most of the included studies showed improved cognitive outcome post-cranioplasty, however quantitative analysis was not possible due to varied study design. A considerable proportion of post-DC patients experience depression and anxiety. Selective screening can improve early detection and resource allocation. Future studies should focus on developing targeted patient pathways.
No takes yet. Share an insight, caveat, or question.
Bari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: